Table 2.
Treatment Characteristics: Percentage of Patients per Cycle Who Received Full Therapy
Characteristic | % of Patients per Cycle Who Received Full Therapy
|
|
---|---|---|
CVD Arm | BCT Arm | |
Cycle 1 | n = 187 | n = 177 |
Cisplatin | 99 | 93 |
Vinblastine | 98 | 95 |
Dacarbazine | 99 | 98 |
IL-2 | 87 | |
IFN | 60 | |
Cycle 2 | n = 159 | n = 154 |
Cisplatin | 97 | 84 |
Vinblastine | 93 | 82 |
Dacarbazine | 94 | 84 |
IL-2 | 73 | |
IFN | 57 | |
Cycle 3 | n = 93 | n = 96 |
Cisplatin | 97 | 80 |
Vinblastine | 92 | 71 |
Dacarbazine | 91 | 74 |
IL-2 | 67 | |
IFN | 40 | |
Cycle 4 | n = 81 | n = 82 |
Cisplatin | 94 | 72 |
Vinblastine | 80 | 59 |
Dacarbazine | 81 | 60 |
IL-2 | 57 | |
IFN | 37 |
Abbreviations: CVD, cisplatin, vinblastine, and dacarbazine; BCT, biochemotherapy; IL-2, interleukin-2; IFN, interferon alfa-2b.